CURING LOCALIZED IMMUNE CONDITIONS
Starting with Type 1 Diabetes
At Rezq Bio, our mission is to re-educate the immune system — not suppress it
We have engineered a platform that pairs two distinct delivery modalities with an indication-agnostic architecture, facilitating rapid expansion across autoimmune and transplant landscapes with minimal modification
TREATMENT DELIVERY MODALITIES
● An autologous dendritic cell therapy that has established human safety with negligible side effects
● A microsphere delivery system that has demonstrated preclinical parity to our cell-based therapy
CLINICAL APPLICATIONS
● Treating autoimmune disease directly as a monotherapy — quieting localized inflammation. Type 1 Diabetes is our lighthouse indication, with IBD and other diseases where immune pathology is concentrated soon following
● Shielding transplanted cells as a combination therapy — maximizing graft survival and minimizing the systemic burden of traditional immunosuppressants. Islet cell grafts will be the first to be potentiated by our technology
T1D IS A global PROBLEM WITH NO SOLUTION
64k
New U.S. Diagnoses Annually
2M
Patients Currently in the U.S.
18M
Patients Worldwide by 2040
$85B
Economic Impact Globally
NO LONGEr A JUVENILE CONDITION
In a 2023 study from Johns Hopkins Bloomberg School of Public Health:
● Up to 62% of T1D cases develop in patients older than 20 (median 24 years)
● 37% of patients were diagnosed after 30 years
LACK OF EFFECTIVE TREATMENTS
There are no FDA-approved therapies for TID proven to…
● Prevent disease onset
● Arrest its progression or
● Restore insulin production safely
treatment options
platform
Our approach focuses on dendritic cells as they are the regulator cells of the immune system. They can create an inflammatory or tolerant environment
We use our technological platform to convert dendritic cells from a mature (mDC) or inflammatory state, into an immature (iDC) or tolerant state
Our lead P1B/2A ready autologous dendritic cell therapy does this ex-vivo while our microsphere loaded version has performed this preclinically in situ with equally strong performance
Through regional targeting, we can turn off unwanted immune responses locally while not suppressing the entire immune system
Pipeline
Rezq’s pipeline is led by our cell therapy designed to treat early onset T1D. With promising in-human safety it provides a launching point for our multi-disease, dual-application and dual delivery method platform
people
We have built careers in healthcare and are passionate about curing T1D and autoimmune disease
Board and Advisory
We are fortunate to have an accomplished Board and Advisory that believe in our team, science and mission to treat autoimmune disease
